Sunshine Hospital

The trials here

What the 26 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease6 trials
• Lung cancer4 trials
• Metastatic breast cancer4 trials
• Prostate cancer4 trials
• IgA nephropathy2 trials
• Bladder cancer1 trial
• Brain metastases1 trial
• Childhood cancers1 trial
• Coronary artery disease1 trial
• Diabetic eye disease1 trial
• Kidney cancer1 trial
• Multiple myeloma1 trial
• and 3 more

Phase

• Phase 317 trials
• Phase 1/23 trials
• Phase 23 trials
• Phase 2/33 trials

Status

• Active, not recruiting12 trials
• Completed8 trials
• Recruiting4 trials
• Terminated1 trial
• Withdrawn1 trial

Lead sponsor

• Hoffmann-La Roche8 trials
• University of Sydney4 trials
• Pfizer2 trials
• Akeso1 trial
• Bayer1 trial
• and 10 more

Running trials

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT06162572· Phase 1/2· Servier Bio-Innovation LLC· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

  NCT06203210· Phase 3· Daiichi Sankyo· Source

  Contact: Principal Investigator

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

  Contact: Trial Registration Coordinator

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

  NCT06065748· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

  NCT05797610· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension

  NCT05678621· Phase 2/3· Monash University· Source

  Contact: Prof Zoe McQuilten

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

  NCT04576455· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

  NCT04546009· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

  NCT05593094· Phase 1/2· Hoffmann-La Roche· Source

• Active, not recruiting

  Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

  NCT04136353· Phase 3· University of Sydney· Source

• Active, not recruiting

  The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.

  NCT01320345· Phase 3· University of Sydney· Source

• Active, not recruiting

  Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

  NCT02811861· Phase 3· Eisai Inc.· Source

• Active, not recruiting

  Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

  NCT02319837· Phase 3· Pfizer· Source

• Active, not recruiting

  Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

  NCT02446444· Phase 3· University of Sydney· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Peripheral artery disease1 recruiting

Closed trials

• Completed

  Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

  NCT05834738· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

  NCT05852691· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer

  NCT05505825· Phase 1/2· Akeso· Source

• Completed

  A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

  NCT05047263· Phase 3· Bayer· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Terminated

  Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04921358· Phase 3· BeiGene· Source

• Completed

  Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

  NCT03969953· Phase 3· The George Institute· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

  NCT02582697· Phase 3· University of Sydney· Source

  Contact: P3BEP Trial Coordinator

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source